Please ensure Javascript is enabled for purposes of website accessibility

Golf Clap for AmSurg

By Seth Jayson - Updated Apr 10, 2017 at 1:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Just the facts, Fool.

AmSurg (Nasdaq: AMSG) reported earnings on April 23. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), AmSurg met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded. Non-GAAP earnings per share grew. GAAP earnings per share expanded significantly.

Gross margins grew, operating margins dropped, net margins increased.

Revenue details
AmSurg logged revenue of $260.1 million. The seven analysts polled by S&P Capital IQ hoped for a top line of $261.4 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $230.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.52. The eight earnings estimates compiled by S&P Capital IQ predicted $0.52 per share. Non-GAAP EPS of $0.52 for Q1 were 4.0% higher than the prior-year quarter's $0.50 per share. (The prior-year quarter included -$0.03 per share in earnings from discontinued operations.) GAAP EPS of $0.56 for Q1 were 19% higher than the prior-year quarter's $0.47 per share. (The prior-year quarter included -$0.03 per share in earnings from discontinued operations.)

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 85.5%, much better than the prior-year quarter. Operating margin was 30.6%, 20 basis points worse than the prior-year quarter. Net margin was 6.8%, 40 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $266.1 million. On the bottom line, the average EPS estimate is $0.55.

Next year's average estimate for revenue is $1.07 billion. The average EPS estimate is $2.18.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 141 members out of 149 rating the stock outperform, and eight members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give AmSurg a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AmSurg is hold, with an average price target of $29.50.

Is AmSurg the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Envision Healthcare Corporation Stock Quote
Envision Healthcare Corporation
AMSG.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.